Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 150

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 150
---
 NLS has a license agreement, and also serves as the President of Aexon. Mr. Zwyer holds no board or executive position at Aexon Labs, Inc., or Aexon. Mr. Zwyer and Mr. Konofal may have interests in the transactions with Aexon that may be different from, or in addition to, the interests of its shareholders and that may create potential conflicts of interest. Each of NLS and Aexon expect to be required to obtain additional liquidity in order to fund operations through the approval of certain of each of the company’s products. Until each company can generate significant revenues, if ever, each company expects to satisfy its future cash needs through debt or equity financings. Each company cannot be certain that funding will be available to it on acceptable terms, if at all. If funds are not available, each company may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to each company’s products. NLS expects that it will need to raise substantial additional funding before NLS can expect to complete the development of Quilience or any other product candidate. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force it to delay, limit or terminate its product candidate development efforts or other operations. As of December 31, 2024, NLS’s cash and cash equivalents were approximately $1.7 million, and NLS had a positive working capital of $1.4 million and an accumulated deficit of $74.4 million. Based upon its currently expected level of operating expenditures, NLS believes that its current cash on hand and access to existing financial arrangements 42 will not be sufficient to fund its projected operating requirements for a period of one year from the issuance of these financial statements included elsewhere in this proxy statement/prospectus. This raises substantial doubt about its ability to continue as a going concern. NLS expects that it will require substantial additional capital to commercialize its product candidates and put in place multiple options to raise the funds necessary to support its operations. However, its operating plans may change as a result of many factors that may currently be unknown to us, and NLS may need to seek additional funds sooner than planned. Its future funding requirements will depend on many factors, including but not limited to: •our clinical trial results and the costs for conducting pivotal trials; •the cost, timing and outcomes of seeking marketing approval of Qu